Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 59, Issue 2, 1999, Pages 125-132

  Diaz Martin M A ^a   Traba, M L ^a   De La Piedra, C ^a   Guerrero, R ^a   Mendez Davila C ^a   Garcia De La Pena E ^a,b  

^a Bone and Mineral Metab Laboratory   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Alkaline phosphatase; Aminoterminal propeptide of procollagen I; Bone alkaline phosphatase; Bone metastases; Prostate specific antigen; Prostatic carcinoma

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1; ISOENZYME; PEPTIDE; PROCOLLAGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE METASTASIS; CROSS REACTION; DISEASE CLASSIFICATION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSSIFICATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RADIOIMMUNOASSAY;

AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032915468     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519950185850     Document Type: Article

References (21)

1. Roberts JG, Gravelle IH, Baum M, Bligh AS, Leach KG, Hughes LE. Evaluation of radiography and isotopic scintigraphy for detecting skeletal metastases in breast cancer. Lancet 1976; i: 237-9.
2. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 295-302.
3. O'Donoghue JM, Rogers E, Grimes H, et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Rad 1993; 66: 672-81.
4. Delmas PD. Biochemical markers of bone remodeling in osteoporosis. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, editors. Osteoporosis 96. International Congress, series 1118. Amsterdam: Elsevier, 1996: 191-204.
5. Kostenuit PJ, Sanchez Sweatman O, Orv FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 1996; 14: 19-26.
6. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-51.
7. Risteli L. Marcadores óseos procedentes del colágeno tipo I: PICP, ICTP y PINP. Revista Española de Enfermedades Metabólicas Óseas 1996; 5: 81-5.
8. Schröder FH, Hermanek P, Denis WR, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The Prostate Supplement 1992; 4: 129-38.
9. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for the intact aminoterminal propeptide of human type 1 procollagen. Clin Chem 1996; 42: 947-54.
10. Panigrahi K, Delmans PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline-phosphatase in serum. Clin Chem 1994; 40: 822-8.
11. Withold W, Schulte U, Reinaver H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem 1996; 42: 210-7.
12. Dominguez C, Sosa M, De la Piedra C, Traba ML. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporosis Int 1998; 8: 147-51.
13. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-68.
14. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
15. Goldberg DM, Ellis G. An assessment of serum acid and alkaline phosphatase determinations in prostatic cancer with a clinical validation of an acid phosphatase assay utilizing adenosine 3′-monophosphate as substrate. J Clin Pathol 1974; 27: 140-4.
16. Wajsman Z, Chu T, Bross D, et al. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma. J Urol 1978; 119: 244-50.
17. Díaz Martín MA, Martín I, Soldevilla MJ, et al. Estudio de la reactividad cruzada en la determinación de la isoenzima ósea de la fosfatasa alcalina por dos métodos: Tandem R-Ostase y Alkphase-B, el primero un IRMA y el segundo un ELISA. Revista Española de Enfermedades Metabólicas Óseas 1995; 4 (Suppl A): 21.
18. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77: 1046-53.
19. Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninutto M, Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin Chim Acta 1994; 226: 151-8.
20. Houzé P, Ranaivosoar R, Prost AC, Lonchampt MF. Metastases osseuses des cancers de la prostate: apport du dosage spécifique de la phosphatase alkaline osseuse. Immunoanal Biol Spec 1995; 10: 27-33.
21. Casetta G, Gamba P, Piana P, Pecchio F, Tizzani A. Measurement of skeletal alkaline phosphatase in prostatic carcinoma 1995; Minerva Urol Nefrol 47: 9-12.